Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.
Chathuri Abeyakoon, Esther Ting, Sahar Khan, Manjula Maganti, Sita Bhella, Michael Crump, David Hodgson, Robert Kridel, Vishal Kukreti, John Kuruvilla, Abi Vijenthira, Chloe Yang, Danielle Rodin, Richard Tsang, Anca Prica
{"title":"Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.","authors":"Chathuri Abeyakoon, Esther Ting, Sahar Khan, Manjula Maganti, Sita Bhella, Michael Crump, David Hodgson, Robert Kridel, Vishal Kukreti, John Kuruvilla, Abi Vijenthira, Chloe Yang, Danielle Rodin, Richard Tsang, Anca Prica","doi":"10.1080/10428194.2025.2467801","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2467801","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor